Determining the Potential for Efficacy of OTX-601 in Reducing PTSD Symptoms
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorOui Therapeutics, Inc.
About this trial
This study is exploring the efficacy of a digital therapeutic app in reducing symptoms of posttraumatic stress disorder (PTSD) in adults.
Eligibility criteria
Qualifiers
Posttraumatic stress disorder (PTSD) diagnosis
Anxiety Sensitivity Index 3 (ASI-3) scores above 24
PTSD Checklist for DSM-V (PCL-5) scores above 30
Understands and speaks English
Disqualifiers
Score of 24 or lower on the ASI-3
Score of 30 and below on the PCL-5
No PTSD diagnosis
Active psychosis
Trial design
Treatments tested in this trial
- OTX-601 Digital Therapeutic
- OTX-003 Comparator app
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
Oui Therapeutics, Inc.
Lead sponsor
National Institute of Mental Health (NIMH)
Collaborator
Florida State University
Collaborator
Source ClinicalTrials.gov